In the latest in a series of life sciences SPAC mergers, Ligand Pharmaceuticals (Nasdaq: LGND) is to use the approach to hive off its antibody business.
The company’s antibody discovery biotech, OmniAb, will be spun-out and then immediately merged with a newly-formed subsidiary of Avista Public Acquisition Corp II (APAC), a blank check company.
APAC, a private equity firm focused on the healthcare industry, will invest up to $115 million in the combined company, whereas Ligand will contribute $15 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze